Regorafenib will be the Only Approved Agent in the Second Line

Regorafenib will be the Only Approved Agent in the Second Line

obr

3 years
593 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses regorafenib in clinical practice at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Up Next Autoplay